U.S. FDA Removes 27 Ranbaxy Generic Applications As Part Of Decree
This article was originally published in PharmAsia News
Executive Summary
The U.S. FDA removed 27 Ranbaxy Laboratories applications for since-withdrawn generics as prescribed by a consent decree with the company earlier this year.